newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - KORSANA BIOSCIENCES INC

  • Financial Performance:

    • The company is privately held; specific revenue, earnings, or profit margins were not disclosed as the focus is on early-stage clinical development.
    • Cash position: Over $450 million in funding secured through 2029 as of September end.
    • No debt or cash flow metrics were discussed; capital is dedicated to advancing the lead candidate, KRSA-028.
  • Guidance and Future Outlook:

    • Clinical Milestones: Targeting first data disclosure (Single Ascending Dose in healthy volunteers) in mid-2027; Interim Proof of Concept (Multiple Ascending Dose/Plaque Reduction) data expected by late 2027 or Q1 2028.
    • Phase 3 Start: Planning to initiate global Phase 3 trials in 2028 following the completion of Phase 1b/2 expansion cohorts for safety and dose confirmation.
    • Long-term Goals: Aiming for a best-in-class profile with monthly subcutaneous (SC) low-volume dosing via auto-injector for at-home use.
    • Market Expansion: Positioned to capitalize on potential double-digit market expansion if pre-symptomatic Alzheimer's trials (e.g., Lilly's Trailblazer-ALZ3) validate earlier intervention opportunities.
  • Business Segments and Product Lines:

    • Lead Program: KRSA-028, an A-beta TFR blood-brain shuttle candidate developed in partnership with Paragon Laboratories.
    • Mechanism of Action: Targets pyroglutamate-modified amyloid plaques (similar to Lilly's denanumab/remternetug) using a transferrin receptor shuttle for enhanced BBB penetration.
    • Key Differentiators:
      • FC Region Engineering: Modified to extend half-life (via YTE-like mechanism), preserve phagocytosis (plaque clearance), but eliminate CDC and ADCC to mitigate anemia and infusion reactions seen with competitors.
      • Dosing Strategy: Designed for low-dose, monthly subcutaneous administration, contrasting with the high-dose IV regimens of current approved therapies.
    • Partnerships: Collaboration with Paragon Laboratories for molecule design; no other commercial product lines mentioned.
  • Market and Competitive Landscape:

    • Competitors: Roche (Trobanumab/Trontinemab), Eli Lilly (Denanumab, Remternetug), Biogen (Leqembi).
    • Market Trends: Shift toward disease-modifying therapies with improved safety profiles (reduced ARIA) and convenience (SC vs. IV). Roche's Phase 3 readout expected in H1 2028 is a critical industry catalyst.
    • Competitive Advantage: Belief that KRSA-028 matches Roche's plaque clearance speed/depth while offering a superior safety profile (lower ARIA, no anemia) and superior dosing convenience (monthly SC vs. IV).
    • Market Size: Potential to double the Total Addressable Market (TAM) if pre-symptomatic population (asymptomatic amyloid-positive) is successfully treated, driven by safety improvements.
  • Risks and Challenges:

    • Safety Concerns: Primary risks include Antigen-Risk Associated Amyloidosis (ARIA) and anemia, though management claims engineering mitigates these compared to unshuttled antibodies and Roche's current offering.
    • Clinical Risk: Failure to match Roche's plaque clearance trajectory or achieve the targeted CSF-to-serum ratio (7-8x) in early human data.
    • Regulatory: Need to adequately characterize safety in expansion cohorts to gain global regulator buy-in for Phase 3.
    • Competition: Presence of other TFR shuttle candidates (e.g., Denali) and the possibility that pre-symptomatic data fails to materialize as expected.
  • Management Commentary and Tone:

    • Tone: Highly confident and bullish; management expresses certainty that the current standard of care (IV antibodies) has significant liabilities (safety, convenience) that their technology solves.
    • Strategy: Focuses on "least risky approach" by building upon the validated mechanism of Roche's Trontinemab while optimizing the Fc region for safety and PK/PD.
    • Vision: Positioned as a pure-play company dedicated solely to advancing KRSA-028 to become the standard of care for Alzheimer's.
  • Analyst Questions and Answers:

    • Efficacy vs. Roche: Management asserts KRSA-028 will achieve at least equal plaque clearance to Trontinemab (approx. 50%+ reduction, amyloid negativity in 3-6 months) due to the pyroglutamate targeting and shuttle efficiency.
    • Safety Mechanism: Explained that lower peripheral exposure required by the shuttle reduces local immune responses on vasculature, thereby lowering ARIA rates compared to high-dose IV unshuttled antibodies.
    • Dosing & PK: Clarified that half-life extension allows for lower monthly doses rather than infrequent long-dosing; targeting a CSF:serum ratio of 7-8x (matching Roche) to confirm shuttle functionality.
    • Market Dynamics: Confirmed that Roche's H1 2028 readout could validate the TFR shuttle class, and positive pre-symptomatic data (potentially 2027) could expand the market significantly.
  • Other Key Points:

    • Pre-clinical Data: Non-human primate data supports the ~150 mg monthly SC dose hypothesis; mouse data suggests diffuse brain penetration reduces vascular crowding.
    • Regulatory Precedent: Cited Leqembi's transition from IV to SC as validation that matching C-average exposure (AUC) is sufficient for FDA approval of SC formulations.
    • Competitor Landscape: Acknowledged AbbVie's acquisition of a shuttle competitor and Denali's Phase 1 activity, but maintains KRSA-028's engineering is the most de-risked path.
    • Data Milestones: Single Ascending Dose (SAD) data will specifically look for local tolerability, anemia markers (CBC), and CSF penetration ratios.
Company
KORSANA BIOSCIENCES INC
Keywords
KORSANA BIOSCIENCES INC